This presentation is dedicated to Dr. Albert Sabin, one of the great heroes of 20th century pediatric research, in recognition of his many significant contributions to the health of children and the distinction he has brought to American pediatrics and the American Pediatric Society.
This Centennial Meeting is an appropriate occasion to celebrate the important role American pediatrics has played in bringing a number of important viral diseases under control. Preventive medicine has been a major activity of the American Pediatric Society and its members have made a disproportionately large contribution to the development of safe, effective viral vaccines.
Currently, effective licensed vaccines are available for prevention of disease caused by 10 distinct human viruses or viral groups. The first of these vaccines, vaccinia virus, was developed by Jenner 190 years ago for the prevention of smallpox. Ninety years elapsed until the rabies virus vaccine was developed by Pasteur. During the last 50 years, the pace of discovery and development accelerated and vaccines for eight additional viruses or virus groups were added to our armamentarium. Members of the American Pediatric Society played an essential role in the development of vaccines for five of these eight viruses or virus groups: inactivated poliovirus vaccine, John Enders, Thomas Weller, and Frederick Robbins; live poliovirus vaccine, Albert Sabin; live measles virus vaccine, John Enders and Samuel Katz; live rubella virus vaccine, Hany Meyer and Stanley Plotkin; live adenovirus vaccine, Robert Chanock; and inactivated hepatitis B virus (HBV) vaccine, Saul Krugman.
It should be noted that eight of the 10 viral diseases against which effective vaccines are now available are caused by viruses that produce a systemic infection. This is not surprising because small amounts of serum antibodies are usually highly effective in preventing disease caused by viruses that spread systematically. In contrast, the requirements for effective immunization against a topical infection in which virus produces its disease manifestations at the site of implantation are more demanding because locally produced mucosal antibodies and/or a high concentration of serum antibodies are needed for resistance.
LIVE VIRUS VACCINES
Except for the adenoviruses, type 2 poliovirus and vaccinia virus, the licensed live vaccine strains were attenuated during serial propagation in cell culture. Satisfactory attenuation and antigenicity of vaccinia, measles, mumps, rubella, and adenovirus vaccine strains were determined exclusively by clinical evaluation in susceptible individuals (1).
During the development of live vaccines for yellow fever and poliomyelitis, studies in experimental animals provided a strong signal that mutants with the desired phenotype and level of attenuation had been selected by passage of virus in cell culture or had been recovered directly from an asymptomatically infected individual. The 17D vaccine mutant of tissue cultureadapted yellow fever virus was identified by its decreased tropism S for the liver of experimentally infected monkeys (2). Later, clinical studies indicated that the mutant was satisfactorily attenuated and antigenic in humans. Similarly, naturally occuning or laboratory-selected mutants of poliovirus with markedly reduced neurovirulence for the spinal cord were identified by studies in monkeys (3, 4). These candidate poliovirus vaccine strains were then subjected to additional cycles of selection that led to the identification of mutants that replicated with high efficiency in the intestinal tract without significant increase in neurovirulence for nonhuman primates. The optimal strains selected in this manner were then shown to be satisfactorily attenuated and antigenic in susceptible individuals.
The molecular basis for attenuation of the measles, mumps, and rubella virus vaccine strains is not known. It is known, however, for the live vaccine strains of type 1 and type 3 poliovirus. During the course of its attenuation, the type 1 strain sustained 56 nucleotide substitutions that resulted in 2 1 amino acid changes (5). Analysis of chimeric infectious cDNA constructed from the virulent parental type 1 virus and its attenuated vaccine derivative indicates that mutations responsible for attenuation are scattered throughout the 7.5 kb RNA viral genome (6). The type 3 vaccine strain sustained fewer mutations and this is thought to be the explanation for the fact that its attenuation is less stable than that of the type 1 vaccine strain. Ten nucleotide substitutions occurred in the type 3 vaccine strain resulting in only three amino acid changes (7). Molecular genetic analysis of the type 3 vaccine strain indicated that only two mutations play a prominent role in attenuation: a nucleotide substitution in the 5' noncoding region of the genome and an amino acid substitution in the viral VP3 capsid protein (8, 9). The type 2 vaccine strain is a naturally occuning attenuated mutant and the basis of its attenuation is not known at this time.
During the course of its attenuation, the yellow fever virus 17D vaccine strain sustained 32 amino acid substitutions in its entire complement of viral proteins (10). It is perhaps significant that 40% of these mutations clustered in the viral envelope glycoprotein that is responsible for adsorption of virus to the host cell.
Finally, it should be noted that live virus vaccine strains do not necessarily have to be attenuated to produce an asymptomatic immunizing infection. An example of this apparent paradox is the live type 4 and type 7 adenovirus vaccine, which is now used routinely for prevention of adenovirus respiratory tract disease in military recruits (1 I , 12). During the development of this vaccine, we did not attempt to attenuate the vaccine strains. Instead, attenuation was achieved by confining infection to a region of the body in which symptoms fail to develop. Oral administration of enteric-coated type 4 and type 7 adenovirus produces a silent infection limited to the intestines. Infection does not spread back to the respiratory tract, which is the usual site of disease produced by these viruses. Ordinarily, adult vaccinees do not transmit infection to their close contacts.
The pace at which new vaccines are introduced into pediatric practice should accelerate during the next decade. Vaccines for S40 CHA NOCK seven additional viruses are imminent or in various stages of development. The most imminent is the live varicella virus vaccine that could be licensed within a few years (13, 14). Probably next in line is a live virus vaccine for rotavirus diarrheal disease.
INACTIVATED VACCINES
Before discussing the newer vaccines under development, many of which are live and attenuated, it should be noted that live viral vaccines offer several significant potential advantages over inactivated or subunit viral vaccines. However, a live viral vaccine is not suitable for every situation. For example, subunit vaccines are mandatory for viruses such as HIV and HBV that integrate into the host genome and cause persistent infection. Indeed, one of the major recent successes in pediatric immunoprophylaxis has been the inactivated hepatitis B virus vaccine that contains purified HBV surface antigen (HBsAg). In one study, immunization of neonates with purified HBsAg reduced the frequency of transmission of HBV from highly infectious, chronically infected members (HBeAg positive) to their infants by 89% (15). This protection was achieved without concurrent administration of hepatitis B immune globulin (HBIG) and in the face of a transmission frequency of 65% in the placebo group. Vaccine efficacy in this situation is of considerable public health importance because infants infected near or during delivery are at high risk of becoming chronic carriers of HBV and developing chronic hepatitis and/or primary hepatocellular carcinoma (16,
Recently, several encouraging developments have suggested that effective immunization against respiratory syncytial virus (RSV) may be achievable with purified viral surface antigens (18). RSV F and G glycoproteins were purified from a lysate of infected cells by immunoaffinity chromatography, and immunization of cotton rats with either glycoprotein induced complete resistance to RSV infection in the lungs (18). There was no evidence of enhanced pulmonary pathology in the immunized animals following challenge with RSV. Clinical trials of a purified RSV F glycoprotein vaccine are now underway.
ADVANTAGES AND DISADVANTAGES O F LIVE VIRUS VACCINES
Among the advantages of live viral vaccines are induction of more effective local mucosal immunity and greater duration of immunity. Also, during infection, protective viral antigens are displayed in their mature configuration on the virus and in some instances on the surface of infected cells. Processed viral antigens are also displayed at the surface of infected cells. These features of antigen presentation favor the induction of an effective, balanced response of neutralizing antibodies and cell-mediated immunity. The most serious potential disadvantage of live viral vaccines is the possibility that genetic instability could lead to loss of attenuation.
STRATEGIES EMPLOYED T O MINIMIZE GENETIC INSTABILITY
Six different strategies are now being employed to minimize the possibility of genetic instability without compromising the proper balance between attenuation and immunogenicity required of all live viral vaccine strains.
Jennerian Approach. The first strategy is the Jennerian approach which involves the use of an animal or avian virus that is related antigenically to a human virus. Animal and avian viruses that are well adapted to their natural host often do not replicate efficiently in humans and hence are attenuated for man. This type of attenuation is usually quite stable as a consequence of the significant divergence of the animal or avian viral genes involved in host range restriction from the corresponding human viral genes.
Bovine parainfluenza type 3 virus. A recent example of the
Jennerian approach is the bovine parainfluenza type 3 virus (bovine PIV3). Human parainfluenza virus type 3 is a paramyxovirus that is second in importance only to RSV as an etiologic agent of serious pediatric viral respiratory tract disease. Bovine PIV3 shares several neutralization epitopes with human PIV3 but these two viruses exhibit significant divergence of sequence (19, 20) . Nonetheless, infection of cotton rats and monkeys with bovine PIV3 induces significant resistance to human PIV3 (2 1). Furthermore, bovine PIV3 is restricted in the lower respiratory tract of rhesus monkeys and chimpanzees (2 I). These encouraging observations concerning attenuation and protective efficacy provide a rationale for clinical evaluation of bovine PIV3 as a live vaccine for prevention of human PIV3 disease.
Modified Jennerian Approach for Use with Viruses Possessing a Segmented Genome. Avian x human influenza A virus reassortants.
The Jennerian approach has recently been modified to take advantage of the segmented genome of some avian and animal viruses that are attenuated in humans. In this situation, attenuating genes that code for nonsurface proteins, so-called "internal genes," can be transferred by gene reassortment into a reassortant ("hybrid") virus that derives its genes for protective surface antigens from a related human virus. For example, the internal genes of influenza A virus are its three polymerase genes and the nucleoprotein, matrix protein, and nonstructural protein genes. These six internal genes of an avian influenza A virus that is attenuated for experimental primates have been transferred into a reassortant virus that derived its genes for the hemagglutinin (HA) and neuraminidase (NA) protective surface antigens from a human influenza A virus (22). Reassortant viruses prepared by us in this manner from the attenuated avian influenza A donor virus and a series of virulent human influenza A viruses were as restricted in the lower respiratory tract of monkeys as the avian influenza A virus itself (23). In subsequent clinical trials in susceptible adults, and in some instances in infants and young children as well, these reassortant viruses have consistently been satisfactorily attenuated and immunogenic (22, 24).
Subsequent analysis indicated that four of the six internal avian influenza A virus genes played a role in host rangerestriction (25). The polygenic nature of avian influenza A virus host range-restriction in humans is encouraging because it is unlikely that all of the avian influenza A virus genes responsible for attenuation could simultaneously develop the full complement of mutations required for human virulence, especially since avian influenza A virus reassortants produce a restricted infection in susceptible humans (22).
Rotaviruses. Rotaviruses are the single most important group of etiologic agents of severe diarrhea of infants and young children throughout the world (26). Thus, the need for an effective rotavirus vaccine is now clear, particularly in developing countries where rotavirus disease appears to be a leading cause of mortality during the first two years of life. We are currently evaluating an animal rotavirus strain, rhesus rotavirus (RRV), as a vaccine candidate (26). This simian rotavirus has not been recovered under natural conditions from man and, thus, it is not a virus of human heritage. Although the genes of RRV exhibit significant divergence in sequence from the corresponding genes of human rotaviruses, this simian rotavirus is similar to human rotavirus serotype 3 when tested by neutralization (26). Most promising are the results from a recent clinical trial in 247 young infants in Venezuela in which protective efficacy was 68% overall and 100% for the most severe forms of rotavirus diarrhea (27) . In this study, the predominant rotavirus strain recovered from patients with diarrhea belonged to the same serotype as the vaccine virus. However, the vaccine proved to be ineffective in two other studies in which the predominant infecting strain belonged to a different serotype than RRV. This suggests that serotype-specific immunity is required in some circumstances for satisfactory protection against rotavirus diar-CONTROL OF PEDIAT 'RIC VIRAL DISEASES s4 1 rhea. Because of the need for a multivalent vaccine that will induce resistance to each of the four human rotavirus serotypes, we modified the Jennerian approach by constructing reassortant viruses that contain 10 RRV genes plus a single human rotavirus gene that codes for the major neutralization antigen (VP7) responsible for serotype specificity (28, 29). These single-gene substitution RRV reassortants with the attenuation characteristics of the rhesus virus and the neutralization specificity of human rotavirus serotype 1, 2, or 4 are now being evaluated in phase 1 and phase 2 clinical trials. To date, the reassortants appear to be as attenuated and immunogenic as RRV. RRV and its reassortants induce a transient febrile response in approximately one third of 2-to 6-month-old vaccinees. However, fever does not occur when RRV is fed during the first month of life, but the vaccine is still immunogenic.
Another animal rotavirus, bovine strain WC3 (serotype 6), has also been studied as a candidate live vaccine for prevention of rotavirus disease. Initial results have been encouraging and the live attenuated vaccine strain has been shown to provide significant protection against rotavirus disease caused predominantly by serotype 1 virus (30) .
Use of Naturally Attenuated Human Viruses. More than 33 years ago, Albert Sabin observed that strains of poliovirus recovered from healthy individuals exhibited a wide range of neurovirulence as measured by intracerebral or intraspinal inoculation of monkeys (3, 4). Approximately one fifth of these strains were highly attenuated. In fact, the type 2 strain of the live oral poliovirus vaccine was identified in this manner.
Rotaviruses. Rotaviruses cause a wide spectrum of effects ranging from asymptomatic infection in neonates to severe dehydrating diarrheal illness in older infants and young children, but the degree of virulence is not serotype specific because each of the four distinct human rotavirus serotypes has been associated with silent as well as symptomatic infections. During the past few years, rotavirus strains have been recovered from prolonged outbreaks of infection in newborn nurseries in which most affected infants failed to develop significant symptoms. The basis for this naturally occurring attenuation appears to be the fourth rotavirus gene which is highly conserved among asymptomatic nursery strains of all four serotypes (31, 32) . This conserved sequence differs significantly from the conserved fourth gene sequence of virulent rotaviruses of all four serotypes. The product of the fourth gene is a major surface protein (VP4). This protein must be cleaved proteolytically in the intestines for rotavirus to become infectious. The nursery strains of human rotavirus are currently in clinical trial to determine their potential usefulness in prevention of rotavirus disease. Experimentally Produced Deletion Mutants. Attenuation of viral virulence by a deletion mutation of appreciable size has a theoretical appeal because this form of mutation cannot be corrected directly inasmuch as this would require restoration of deleted sequence. Viable deletion mutations can now be produced at specific sites in the genome of DNA viruses, (herpes simplex, adenovirus) or positive-strand RNA viruses (poliovirus). However, it has not been possible to produce specific viable deletions in negative-strand RNA viruses (influenza, RSV) or double-strand RNA viruses (rotaviruses). Some viable deletion mutants of herpes simplex virus are markedly attenuated for experimental animals (33) . Latency is also reduced but is not completely abolished. Fortunately, molecular mechanisms responsible for latency of herpes viruses are now coming into focus and these insights may provide a basis for constructing attenuated deletion mutants that are unable to establish latency. Using a similar strategy, it may be possible to abolish latency of the live varicella vaccine strain.
Experimentally Produced Viable Chimeric Viruses. Recently viable intertypic chimeras (hybrids) of poliovirus were constructed using infectious cloned cDNA. The nucleotide sequence for one of the three antigenic sites of type 3 poliovirus was substituted for the corresponding site of type 1 poliovirus in a type I infectious cDNA clone (34, 35) . The resulting chimeric virus has dual antigenic specificity. Substitution of the entire outer protein surface of type 3 virus for the corresponding region of type 1 virus has also been accomplished yielding a chimeric virus that is solely type 3 in antigenic specificity (36) . Most of the very rare live poliovirus vaccine-associated paralytic illnesses (= I in lo6 immunizations) have been linked to the type 3 vaccine strain. Hence, an intertypic type I-type 3 chimera that is type 1 in sequence except for one antigenic site of type 3 virus or the entire type 3 surface region may prove useful in immunoprophylaxis because it combines type 3 serologic specificity with the greater observed genetic stability of the type 1 vaccine strain.
Experimental (37) . Transfer of the six internal genes of the ca influenza A/Ann Arbor donor mutant to viruses bearing the surface glycoprotein genes of new antigenic variants of influenza A virus regularly attenuates the resulting reassortant viruses for susceptible human volunteers (37) . Furthermore, ca reassortants induce resistance to experimental challenge with virulent human influenza A virus that is equal to or greater than that induced by licensed inactivated influenza A vaccine (38) . Four of the six internal genes of the ca donor virus are independently involved in attenuation (39) . The involvement of multiple genes in attenuation provides a likely explanation for the observed stability of the attenuation phenotype of ca influenza virus reassortants during infection of humans.
Attenuated Viral Vectors that Express Genes Coding for Protective Antigens of Other Viruses.
The sixth approach to the development of safe, effective live vaccines involves the use of a stable attenuated vaccine virus to construct viable recombinants that express the protective antigens of other viruses. To date, the most success has been achieved using vaccinia virus as the recombinant vector (40) . This virus has a large genome with a variety of genes into which foreign viral genes can be inserted and expressed without seriously compromising vaccinia's capacity to replicate. Equally important, vaccinia virus has the longest record of successful use as an effective, attenuated live virus vaccine.
Adenoviruses also have the potential to serve as recombinant vectors for construction of live vaccines because they have a large genome with at least one "nonessential" region as well as several sites into which foreign genes can be inserted and expressed without loss of infectivity (41) . In addition, safe, effective live adenovirus vaccine strains that produce a silent, selective intestinal infection are available for use as viral vectors (I 1, 12).
Respiratory syncytial virus (RSV), parainfluenza virus type 3 (PZV3), and dengue virus. The potential of live recombinant viruses for prevention of viral disease is perhaps best illustrated by initial success in developing an experimental vaccine for prevention of disease caused by RSV. The challenge of vaccination against RSV disease is formidable because the virus has its major impact during the second and third months of life. Thus, we face the difficult task of immunizing very young infants, perhaps newborns. Unfortunately, this is a dificult period in which to attempt immunization because the infant's immunologic processes are not fully responsive to antigenic stimulation. Also, RSV serum antibodies, which are passively acquired from the mother, act to suppress the infant's immunologic response to the protective antigens of RSV (42) .
Previous attempts to develop a safe and effective live or inactivated RSV vaccine have all met with failure. Recent experience with vaccinia virus-RSV glycoprotein recombinants offers hope that effective immunization against RSV can be achieved in the near future. Vaccinia virus recombinants expressing the
